Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01434186 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT01434186 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 32 participants.
The verdict
NCT01434186, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
To evaluate the efficacy, safety, tolerability, of Saxagliptin (BMS-477118) in combination with Metformin in pediatric patients with type 2 diabetes
Interventions
- DRUG Saxagliptin
- DRUG Metformin XR
- DRUG Metformin IR
- DRUG Placebo matching with Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-05 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01434186
The ClinicalTrials.gov registry entry for NCT01434186 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saxagliptin is the first listed.
NCT01434186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01434186 about?
NCT01434186 is a clinical study titled "A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone". To evaluate the efficacy, safety, tolerability, of Saxagliptin (BMS-477118) in combination with Metformin in pediatric patients with type 2 diabetes
What is the current status of trial NCT01434186?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2012-05. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01434186?
The interventions under investigation include: Saxagliptin (DRUG), Metformin XR (DRUG), Metformin IR (DRUG), Placebo matching with Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT01434186?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.